Reintroduction of Diazoxide after Diagnosis of Pulmonary Hypertension in a Patient with Transient Hyperinsulinism

Bahareh Schweiger; Pedro A. Sanchez-Lara; Dor Markush; Pooja Nawathe

doi:10.1055/s-0041-1726462

Journal of Child Science, Inhaltsverzeichnis

CC BY 4.0 · Journal of Child Science 2021; 11(01): e80-e82
DOI: 10.1055/s-0041-1726462

Case Report

Reintroduction of Diazoxide after Diagnosis of Pulmonary Hypertension in a Patient with Transient Hyperinsulinism

Bahareh Schweiger

¹Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates

,

Pedro A. Sanchez-Lara

¹Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates

,

Dor Markush

²Guerin Congenital Heart Program, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United Sates

,

Pooja Nawathe

¹Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates

› Institutsangaben

Abstract

Our case describes the reintroduction of diazoxide despite life-threatening pulmonary hypertension in our infant due to lack of therapeutic options for congenital hyperinsulinism.

Keywords

congenital hyperinsulinism - diazoxide - pulmonary hypertension - chlorothiazide - side effects

Volltext

Referenzen

References
1 Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth 2004; 14 (07) 607-609
2 Welters A, Lerch C, Kummer S. et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis 2015; 10 (01) 150
3 Demirel F, Unal S, Çetin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2011; 24 (7-8): 603-605
4 Herrera A, Vajravelu ME, Givler S. et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab 2018; 103 (12) 4365-4372
5 Nebesio TD, Hoover WC, Caldwell RL, Nitu ME, Eugster EA. Development of pulmonary hypertension in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2007; 20 (08) 939-944
6 Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017; 38 (06) 1247-1250
7 FDA Drug Safety Communication, FDA Warns about a Serious Lung Condition in Infants and Newborns Treated with Proglycem (Diazoxide) [press release]. Food and Drug Administration. Maryland, USA: 2015
8 Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J. Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism. Horm Res Paediatr 2019; 91 (01) 25-32
9 Gray KD, Dudash K, Escobar C. et al; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018; 38 (11) 1496-1502
10 Pediatrics AAo. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127 (03) 575-579
11 Silvani P, Camporesi A. Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol 2007; 5 (02) 129-133
12 Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther 2008; 25 (05) 515-519